Abstract Objective Previous studies have documented a high frequency of thrombotic events in lupus nephritis patients with antiphospholipid (aPL) 
Introduction

Antiphospholipid syndrome (APS) is a disorder characterized by recurrent arterial or venous thrombosis and/or pregnancy morbidity, along with the sustained presence of antiphospholipid (aPL) antibodies in the serum (1). aPL antibodies are a heterogeneous family of pathogenic autoantibodies that act against various phospholipid-binding proteins, and their presence in the serum has been demonstrated to be associated with recurrent thrombosis and fetal loss (2). APS can occur alone as a primary disease or can be secondary to systemic lupus erythematosus (SLE), some infec-
antibodies on the outcomes of lupus nephritis are conflicting, mainly because they are based on studies with short follow-up periods (8) (9) (10) (11) (12) .
In the present study, we retrospectively studied 49 patients with lupus nephritis to evaluate: 1) the seroprevalence of aPL antibodies in patients with lupus nephritis, 2) the clinical and laboratory associations of aPL antibody seropositivity, and 3) possible factors associated with the long-term renal outcomes in these patients.
Patients and Methods
Patients
We performed this retrospective study of (18) .
Statistical analysis
The data were expressed as mean ± SD. 
Results
Clinical and biochemical characteristics at diagnosis of lupus nephritis
T a b l e 1 . Ch a r a c t e r i s t i c s o f t h e P a t i e n t s wi t h L u p u s Ne p h r i t i s S t u d i e d
F i g u r e 1 . T h e p r e v a l e n c e o f t h r o mb o t i c e v e n t s i n l u p u s n e p h r i t i s p a t i e n t s wi t h a n d wi t h o u t a n t i p h o s p h o l i p i d ( a P L ) a n t i b o d i e s i n t h e s e r u m a t p r e s e n t a t i o n .
F i g u r e 2 . T h e p r e v a l e n c e o f a d v a n c e d c h r o n i c k i d n e y d i se a s e ( CKD) wi t h e GF R l e s s t h a n 6 0 mL / mi n / 1 . 7 3 m 2 i n l u p u s n e p h r i t i s p a t i e n t s wi t h a n d wi t h o u t a n t i p h o s p h o l i p i d ( a P L ) a n t i b o d i e s i n t h e i r s e r u m a t t h e f i n a l f o l l o w-u p .
T a b l e 2 . Co mp a r i s o n o f Cl i n i c a l a n d B i o c h e mi c a l P r o f i l e s b e t we e n P r e s e n c e a n d Ab s e n c e o f An t i p h o s p h o l i p i d ( a P L ) An t i b o d i e s i n S t u d y P o p u l a t i o n
Discussion
We have shown that positivity for aPL antibodies in patients with lupus nephritis represents a risk factor for thrombotic events, and also we found an association between the presence of aPL and probability of CKD on long-term follow-up. The prevalence of aPL antibody was similar to that reported in many other studies of patients with SLE (19) , it was also apparently similar to that reported from previous studies of patients with lupus nephritis (7, 8, 12, 20) . Forty-one percent of our patients developed vascular thrombosis, similar to that reported recently for a lupus nephritis series (21) . Because all our patients had nephritis and were followed up for a relatively long period, it is possible that hypertension and atherosclerosis, which are frequent in patients with lupus nephritis, act synergistically with aPL antibodies to produce arterial vasculopathy (22) .
Arterial hypertension is frequent in patients with renal SLE (23) and may be associated with the presence of aPL antibodies (7) (11) or severe proteinuria at presentation (26) , however, these data remain to be confirmed (9, 27) . In the present study, there were no significant differences in the age, sex distribution, eGFR or severity of proteinuria between the aPL antibodypositive and aPL antibody-negative patients at presentation. We found a significant lower prevalence of class V lupus nephritis in aPL antibody-positive patients, although additional studies are needed to confirm this association. Advanced CKD was detected in 9 of the 20 aPL antibodiypositive patients (45%) and 6 patients of the 20 patients were classified with class IV, suggesting that class IV may be associated with the progression of CKD. In previous studies, a number of patients with aPL antibody positivity and nephrotic syndrome showed membranous nephropathy at renal biopsy (28, 29) . This discrepancy is thought to be possibly explained by the differences in the characteristics of the study population.
The present study showed the presence of influence of aPL antibodies on the long-term outcomes of lupus nephritis. Moroni et al (30) 
